The increase in medical insurance rates drives UnitedHealth Group Incorporated (UNH.US) to soar: Wall Street bullish sentiment heats up, why is the only short seller holding firm?

Notice that, despite the stock price of UnitedHealth Group Incorporated (UNH.US) heading towards its best week in seven months after health insurance rates were raised higher than expected, the company's only remaining "bearish" analyst still maintains his bearish prediction. Most of this week's over 10% increase occurred on Tuesday. Previously, the US government announced a 2.48% increase in payment rates for the 2027 federal Medicare Advantage plan, instead of keeping rates essentially unchanged as originally proposed. However, according to Baird analyst Michael Haa, this is just a "temporary placebo" masking other issues. After the news was announced, he kept his "underperform" rating on the stock. Michael Haa became the only analyst to give the stock a "sell" or equivalent rating, after HSBC analyst Sidharth Sahoo upgraded the stock to "hold" on the same day. Michael Haa said, "This may alleviate some concerns about profit growth prospects in the market, but we remind investors not to rush to buy at the moment," "For companies like UnitedHealth Group Incorporated with significant exposure in the value-based healthcare sector, they are still not out of the woods." Analysts are generally optimistic about UnitedHealth Group Incorporated The final payment policy determined by the Centers for Medicare & Medicaid Services (CMS) is widely seen as a "reprieve" for health insurance companies facing squeezed profits. For over a decade, the Medicare Advantage program has been the engine of growth for insurance companies, but with rising healthcare costs and reduced government funding, the profitability of this business in recent years has declined significantly. For the battered UnitedHealth Group Incorporated - the largest private health insurance provider in the US - this is undoubtedly a booster. The company recently predicted a decrease in revenue in 2026, which would be its first annual contraction in over thirty years; the company also stated that it expects a reduction in the number of enrollees in all major business segments including commercial health plans, Medicare, and Medicaid. Despite a rebound this week, the stock price of this health insurance giant is still down about 7% year-to-date, and more than halved compared to its historical high in 2024. However, Wall Street remains optimistic about UnitedHealth Group Incorporated's bounce off the bottom. Among the 31 analysts tracked by Bloomberg, 22 gave a "buy" rating, with an average 12-month target price about 17% higher than the current stock price.